BASEL--13 Feb--PRNewswire-AsiaNet/InfoQuest
- Results of This Trial Further Confirm the Benefit Avastin Brings to Patients With Breast Cancer.
Roche announced today that a phase III study in metastatic breast cancer investigating Avastin (bevacizumab) in combination with docetaxel chemotherapy compared to docetaxel alone, met its primary endpoint of improving the time patients live without their disease advancing.
The findings come from the first analysis of the phase III "Avastin and Docetaxel" ("AVADO", BO17708) study which investigated the addition of docetaxel to Avastin administered either at 7.5 or 15 mg/kg every 3 weeks. Both doses of Avastin in combination with chemotherapy showed statistically significant improvements in the time patients live without their disease
No new safety signals related to Avastin were observed in the trial.
Dr David Miles, medical oncologist, Mount Vernon Hospital, UK and principal investigator of AVADO, welcomed the news: "Each year more than one million women are diagnosed with breast cancer leading to over 400,000 deaths globally. This study confirms Avastin's effect of prolonging the time in which patients live without their disease getting worse in combination with a widely used
The efficacy and safety data of AVADO will be presented at an upcoming medical meeting.
This second positive phase III trial follows the recently published landmark E2100 study, which formed the basis of European Commission approval of Avastin in combination with paclitaxel for the 1st line treatment of metastatic breast cancer in March 2007. Study E2100 showed that the addition of Avastin to paclitaxel resulted in a doubling of progression-free survival compared to
About the BO17708 study
BO17708 is an international phase III trial which randomized 736 patients who did not receive previous chemotherapy for their metastatic breast cancer to one of three groups;
-- Avastin 7.5 mg/kg every 3 weeks in combination with docetaxel
-- Avastin 15 mg/kg every 3 weeks in combination with docetaxel
-- docetaxel + placebo as control arm
The primary objective of the study was to demonstrate superiority in progression-free survival of both Avastin containing treatment arms compared to the control arm. Secondary endpoints for the study included overall survival, response rate, duration of response, quality of life, safety and tolerability.
About Avastin
Data from the comprehensive Avastin cancer clinical development programme have resulted in approvals in advanced colorectal, breast, lung, and kidney cancer:
-- February 2004 (US) and January 2005 (EU) -- first-line treatment in patients with metastatic colorectal cancer (CRC).
-- June 2006 (US) -- second-line treatment in patients with metastatic CRC.
-- October 2006 (US) -- first-line treatment in patients with advanced non-small cell lung cancer (NSCLC).
-- March 2007 (EU) -- first-line treatment in patients with metastatic breast cancer.
-- April 2007 (Japan) -- treatment in patients with recurrent or advanced CRC.
-- August 2007 (EU) -- first-line treatment in patients with advanced NSCLC.
-- December 2007 (EU) -- first-line treatment in patients with advanced RCC.
-- January 2008 (EU) -- first and later-line treatment in patients with metastatic CRC in combination with any chemotherapy.
All trademarks used or mentioned in this release are legally protected.
Additional information
To access video clips about Avastin, in broadcast standard, free of charge, please go to: http://www.thenewsmarket.com
SOURCE: Roche
CONTACT: Erica Bersin of Roche,
+41-61-688-2164,
[email protected] ; or
Dominic Elliston of Galliard Healthcare,
+44-20-7663-2266,
Web site: http://www.thenewsmarket.com
ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations, representing the first innovation in endocrine therapy in nearly 20 years. ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers, and are a known driver of resistance to standard endocrine therapy, making these tumors more difficult to treat. This agreement includes undisclosed upfront, milestone payments